Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
OMED's Cash-to-Debt is ranked higher than
75% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. OMED: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OMED' s Cash-to-Debt Range Over the Past 10 Years
Min: 290.2  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset -0.12
OMED's Equity-to-Asset is ranked lower than
93% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. OMED: -0.12 )
Ranked among companies with meaningful Equity-to-Asset only.
OMED' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.81  Med: -0.05 Max: 0.35
Current: -0.12
-1.81
0.35
Interest Coverage No Debt
OMED's Interest Coverage is ranked higher than
72% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OMED: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OMED' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -2.71
Beneish M-Score: -5.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -411.06
OMED's Operating Margin % is ranked lower than
67% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. OMED: -411.06 )
Ranked among companies with meaningful Operating Margin % only.
OMED' s Operating Margin % Range Over the Past 10 Years
Min: -411.06  Med: -127.97 Max: -48.52
Current: -411.06
-411.06
-48.52
Net Margin % -409.93
OMED's Net Margin % is ranked lower than
68% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. OMED: -409.93 )
Ranked among companies with meaningful Net Margin % only.
OMED' s Net Margin % Range Over the Past 10 Years
Min: -409.93  Med: -126.42 Max: -47.87
Current: -409.93
-409.93
-47.87
ROA % -49.65
OMED's ROA % is ranked lower than
64% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. OMED: -49.65 )
Ranked among companies with meaningful ROA % only.
OMED' s ROA % Range Over the Past 10 Years
Min: -49.65  Med: -25.92 Max: -12.61
Current: -49.65
-49.65
-12.61
ROC (Joel Greenblatt) % -1160.74
OMED's ROC (Joel Greenblatt) % is ranked lower than
62% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. OMED: -1160.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OMED' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1160.74  Med: -517.34 Max: -385.14
Current: -1160.74
-1160.74
-385.14
3-Year Revenue Growth Rate -35.00
OMED's 3-Year Revenue Growth Rate is ranked lower than
79% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. OMED: -35.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OMED' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -66.1 Max: -35
Current: -35
3-Year EBITDA Growth Rate 22.90
OMED's 3-Year EBITDA Growth Rate is ranked higher than
74% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. OMED: 22.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OMED' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -49.65 Max: 22.9
Current: 22.9
0
22.9
3-Year EPS without NRI Growth Rate 17.60
OMED's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. OMED: 17.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OMED' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.5 Max: 17.6
Current: 17.6
0
17.6
GuruFocus has detected 2 Warning Signs with OncoMed Pharmaceuticals Inc $OMED.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OMED Guru Trades in Q1 2016

Paul Tudor Jones 14,800 sh (New)
First Eagle Investment 184,430 sh (New)
PRIMECAP Management 215,800 sh (+12.51%)
» More
Q2 2016

OMED Guru Trades in Q2 2016

PRIMECAP Management 215,800 sh (unchged)
Paul Tudor Jones Sold Out
First Eagle Investment 77,370 sh (-58.05%)
» More
Q3 2016

OMED Guru Trades in Q3 2016

Jim Simons 251,600 sh (New)
PRIMECAP Management 1,302,700 sh (+503.66%)
First Eagle Investment 230,400 sh (+197.79%)
» More
Q4 2016

OMED Guru Trades in Q4 2016

Jim Simons 469,300 sh (+86.53%)
PRIMECAP Management 1,800,700 sh (+38.23%)
First Eagle Investment 230,400 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with OMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:BTX, NAS:BSTC, NAS:CASC, NAS:ANIP, NAS:BDSI, NAS:BCRX, NAS:BMRN » details
Traded in other countries:O0M.Germany,
OncoMed Pharmaceuticals Inc is a clinical development-stage biopharmaceutical company focused on discovering and developing novel protein therapeutics targeting cancer stem cells, or CSCs.

OncoMed Pharmaceuticals Inc was originally incorporated in July 19, 2004 in Delaware. The Company is a clinical development-stage biopharmaceutical company focused on discovering and developing novel protein therapeutics targeting cancer stem cells, or CSCs. CSCs, also known as tumor-initiating cells, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs exhibit certain properties which include the capacity to divide and give rise to new CSCs via self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. It faces competition from many pharmaceutical and biotechnology companies that are also researching and selling products designed to address these markets. The Company has a total of over 400 patents and pending patent applications in our patent portfolio. The Company's product candidates are subject to regulation by the FDA as biologics.

Ratios

vs
industry
vs
history
Forward PE Ratio 14.29
OMED's Forward PE Ratio is ranked higher than
69% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 20.12 vs. OMED: 14.29 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PS Ratio 11.64
OMED's PS Ratio is ranked higher than
54% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. OMED: 11.64 )
Ranked among companies with meaningful PS Ratio only.
OMED' s PS Ratio Range Over the Past 10 Years
Min: 1.01  Med: 12.24 Max: 26.09
Current: 11.64
1.01
26.09
Current Ratio 3.39
OMED's Current Ratio is ranked lower than
56% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. OMED: 3.39 )
Ranked among companies with meaningful Current Ratio only.
OMED' s Current Ratio Range Over the Past 10 Years
Min: 3.39  Med: 4.77 Max: 6.25
Current: 3.39
3.39
6.25
Quick Ratio 3.39
OMED's Quick Ratio is ranked lower than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. OMED: 3.39 )
Ranked among companies with meaningful Quick Ratio only.
OMED' s Quick Ratio Range Over the Past 10 Years
Min: 3.39  Med: 4.77 Max: 6.25
Current: 3.39
3.39
6.25
Days Sales Outstanding 36.50
OMED's Days Sales Outstanding is ranked higher than
72% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. OMED: 36.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.22  Med: 59.49 Max: 996.38
Current: 36.5
0.22
996.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.10
OMED's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. OMED: -8.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OMED' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -212.7  Med: -107.4 Max: 0
Current: -8.1
-212.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.96
OMED's Price-to-Median-PS-Value is ranked higher than
55% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. OMED: 0.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OMED' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.06 Max: 2.13
Current: 0.96
0.33
2.13
Earnings Yield (Greenblatt) % -64.02
OMED's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. OMED: -64.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OMED' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -78.92  Med: 0 Max: 5000
Current: -64.02
-78.92
5000

More Statistics

Revenue (TTM) (Mil) $25.15
EPS (TTM) $ -3.15
Beta2.69
Short Percentage of Float12.85%
52-Week Range $7.41 - 15.49
Shares Outstanding (Mil)37.40

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 146 54 54
EPS ($) 0.65 -0.37 -0.07
EPS without NRI ($) 0.65 -0.37 -0.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OMED

Headlines

Articles On GuruFocus.com
Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 

More From Other Websites
OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
ONCOMED PHARMACEUTICALS INC Financials Mar 15 2017
OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
ONCOMED PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 09 2017
Edited Transcript of OMED earnings conference call or presentation 8-Mar-17 9:30pm GMT Mar 08 2017
OncoMed reports 4Q loss Mar 08 2017
OncoMed reports 4Q loss Mar 08 2017
ONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 08 2017
OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results Mar 08 2017
Q4 2016 OncoMed Pharmaceuticals Inc Earnings Release - After Market Close Mar 08 2017
OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the... Mar 02 2017
OncoMed Pharmaceuticals to Report Fourth Quarter and Year End Financial Results on March 8, 2017 Mar 01 2017
OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody... Feb 13 2017
OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare... Feb 08 2017
OncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US :... Feb 01 2017
These 5 Stocks Under $10 Could Get Hot Soon Jan 27 2017
OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Brontictuzumab for the Treatment of... Jan 20 2017
OncoMed Pharmaceuticals, Inc. – Value Analysis (NASDAQ:OMED) : January 10, 2017 Jan 10 2017
OncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US :... Jan 09 2017
OncoMed Announces Year-End Cash Balance and 2017 Outlook Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)